Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

3,151.25INR
18 Dec 2014
Price Change (% chg)

Rs-9.10 (-0.29%)
Prev Close
Rs3,160.35
Open
Rs3,200.00
Day's High
Rs3,220.00
Day's Low
Rs3,124.00
Volume
351,199
Avg. Vol
342,943
52-wk High
Rs3,666.25
52-wk Low
Rs2,246.50

REDY.NS

Chart for REDY.NS

About

Dr. Reddy’s Laboratories Limited (DRL) is an integrated global pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active... (more)

Overall

Beta: 0.36
Market Cap (Mil.): Rs538,415.69
Shares Outstanding (Mil.): 170.37
Dividend: 18.00
Yield (%): 0.57

Financials

  REDY.NS Industry Sector
P/E (TTM): 153.65 36.60 37.24
EPS (TTM): 20.57 -- --
ROI: -- 18.95 18.21
ROE: -- 19.73 19.11
Search Stocks

Dr Reddy's Labs gains; Morgan Stanley upgrades to 'overweight'

Shares of India's Dr Reddy's Laboratories gain 0.9 percent.

05 Nov 2014

MARKET EYE-India's Dr Reddy's Labs gains; Morgan Stanley upgrades to 'overweight'

* Shares of India's Dr Reddy's Laboratories gain 0.9 percent. * Morgan Stanley upgrades the stock to "overweight" from "equal-weight"; raises price target to 3,875 rupees from 3,049 rupees. * Says drugmaker's U.S. pipeline outlook has strengthened and valuations appears to be reasonable. * "We expect a better outlook for FY16 and FY17 as underlined by improving India, and US businesses," it said. (indulal.p@thomsonreuters.com/indulal.p.thomsonreuters.com@reut ers.net)

05 Nov 2014

Dr.Reddy's rises; filing shows U.S. market share gains

Reuters Market Eye - Shares in Dr.Reddy's Laboratories gain 1.58 percent vs a 0.02 percent fall in the Nifty.

20 Aug 2014

MARKET EYE -India's Dr.Reddy's rises; filing shows U.S. market share gains

* Shares in India's Dr.Reddy's Laboratories gain 1.1 percent vs a 0.2 percent fall in the NSE index. * A filing with the U.S. Securities and Exchange Commission on Monday shows market share gains in key drugs in the U.S. market, analysts say. (http://1.usa.gov/1tk9u78) (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

20 Aug 2014

MARKET EYE -India's Dr. Reddy's operating profit may lag estimates-StarMine

* India's Dr.Reddy's Laboratories Ltd April-June operating profit may lag consensus, Thomson Reuters StarMine's SmartEstimates shows. * Dr.Reddy's may report operating profit of 7.42 billion rupees ($123.3 million) as per SmartEstimates, versus the consensus mean of 7.70 billion rupees. * Dr.Reddy's reports results later in the day. * Shares up 0.3 percent as of 0500 GMT. ($1 = 60.1700 Indian Rupees) (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

30 Jul 2014

Dr. Reddy's gains as worries about spending ease

Reuters Market Eye - Shares of Dr. Reddy's Laboratories rise, adding to Friday's 1.8 percent gain, after the drugmaker's annual report last week provided key details about spending on building capacity, raising hopes that expenses would reduce after FY16, dealers say.

30 Jun 2014

MARKET EYE-India's Dr. Reddy's gains as worries about spending ease

* Shares of India's Dr. Reddy's Laboratories up 1 percent, adding to Friday's 1.8 percent gain, after the drugmaker's annual report last week provided key details about spending on building capacity, raising hopes that expenses would reduce after FY16, dealers say. * Dr. Reddy's said in its annual report filed with the U.S. Securities and Exchange Commission that the company would finance expansion plans through operating cash flow and through cash and other investments, and that the majority of

30 Jun 2014

Earnings vs. Estimates

Search Stocks